Kurzfassung

A Phase I study to evaluate the safety and clinical activity of WT1-A10+AS01B Antigen-Specific Cancer Immunotherapeutic in adult patients with WT1-positive Acute Myeloid Leukemia in partial remission or complete remission with incomplete blood count recovery post-induction therapy